Skip to Main Content

Paper Details

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
J Clin Invest
14
2021
HLA, HLA-A*01:, Q61K, Q61R, RAS, RAS.Q61K, RAS.Q61K neoantigen, RAS.Q61R, RAS.Q61R variant, T cell receptors, TCR, TCR clones, TCRs, TILs, dominant clone, melanoma, mutated peptide, neoantigen-specific cells, neoantigen-specific clones, patient, patients, tumor, tumor-infiltrating lymphocytes
Author NameAffiliation
Mitchell P LevesqueUniversity Hospital Zurich, University of Zurich
Mitchell P LevesqueUniversity Hospital Zurich, University of Zurich
David J AdamsWellcome Sanger Institute
Richard A ScolyerMelanoma Institute Australia and.
Richard A ScolyerRoyal Prince Alfred Hospital and NSW Health Pathology
Richard A ScolyerThe University of Sydney
Arie AdmonTechnion - Israel Institute of Technology
Steven A RosenbergNational Cancer Institute (NCI)
Steven A RosenbergNational Cancer Institute (NCI)
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology
Nuria Lopez-BigasInstitucio Catalana de Recerca i Estudis Avancats (ICREA)
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology
Nuria Lopez-BigasInstitucio Catalana de Recerca i Estudis Avancats (ICREA)
Ansuman T SatpathyStanford University School of Medicine
Nir FriedmanWeizmann Institute of Science
Yardena Samuels
Yardena Samuels
  • 1 - 17

Datasets

Release 1.2